MX2018013455A - Composiciones y metodos relacionados con inmunogenos de vih-1. - Google Patents
Composiciones y metodos relacionados con inmunogenos de vih-1.Info
- Publication number
- MX2018013455A MX2018013455A MX2018013455A MX2018013455A MX2018013455A MX 2018013455 A MX2018013455 A MX 2018013455A MX 2018013455 A MX2018013455 A MX 2018013455A MX 2018013455 A MX2018013455 A MX 2018013455A MX 2018013455 A MX2018013455 A MX 2018013455A
- Authority
- MX
- Mexico
- Prior art keywords
- hiv
- immunogens
- compositions
- methods related
- contain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229940033332 HIV-1 vaccine Drugs 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000013638 trimer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330604P | 2016-05-02 | 2016-05-02 | |
| PCT/US2017/030375 WO2017192434A1 (en) | 2016-05-02 | 2017-05-01 | Compositions and methods related to hiv-1 immunogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013455A true MX2018013455A (es) | 2019-02-28 |
Family
ID=60203504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013455A MX2018013455A (es) | 2016-05-02 | 2017-05-01 | Composiciones y metodos relacionados con inmunogenos de vih-1. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10647748B2 (https=) |
| EP (1) | EP3452494A4 (https=) |
| JP (1) | JP7046832B2 (https=) |
| CN (1) | CN109153704A (https=) |
| AU (2) | AU2017259275C1 (https=) |
| BR (1) | BR112018072248A2 (https=) |
| CA (1) | CA3022826A1 (https=) |
| EA (1) | EA201892233A1 (https=) |
| IL (2) | IL299962A (https=) |
| MX (1) | MX2018013455A (https=) |
| SG (1) | SG11201809387QA (https=) |
| WO (1) | WO2017192434A1 (https=) |
| ZA (1) | ZA201807216B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11572389B2 (en) * | 2017-01-27 | 2023-02-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| WO2019241483A1 (en) * | 2018-06-13 | 2019-12-19 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
| US20220041650A1 (en) * | 2018-12-03 | 2022-02-10 | Duke University | Purification method for recombinant proteins and nanoparticles |
| US11008368B2 (en) * | 2019-07-26 | 2021-05-18 | The Scripps Research Institute | Engineered HCV E2 immunogens and related vaccine compositions |
| EP4051318A4 (en) * | 2019-10-29 | 2023-10-11 | International AIDS Vaccine Initiative | ENGINEERED ANTI-ENV HIV ANTIBODIES |
| CN114585639A (zh) * | 2019-11-07 | 2022-06-03 | 扬森疫苗与预防公司 | 蛋白质纯化 |
| CN111647078B (zh) * | 2020-06-22 | 2022-04-26 | 中国医学科学院医学生物学研究所 | 一种抗hiv的单克隆抗体及其制备方法和应用 |
| US10906944B2 (en) | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
| EP4245767A4 (en) * | 2020-11-12 | 2025-04-30 | Xiamen University | MODIFIED HUMAN IMMUNODEFICIENCY VIRUS MEMBRANE PROTEIN AND USE THEREOF |
| CN116769053B (zh) * | 2023-05-26 | 2023-12-15 | 华中农业大学 | 重组AaLS-BPP融合肽、制备方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69435171D1 (de) | 1993-09-14 | 2009-01-08 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7939083B2 (en) * | 2006-10-23 | 2011-05-10 | Progenics Pharmaceuticals Inc. | Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain |
| CA2705373A1 (en) | 2007-11-12 | 2009-08-20 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. | Hiv-1 envelope glycoprotein oligomer and methods of use |
| CA2713879C (en) | 2008-02-01 | 2020-01-07 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
| EP2765138B1 (en) * | 2012-11-05 | 2018-01-10 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
| SG10201705880QA (en) | 2013-01-07 | 2017-08-30 | Beth Israel Deaconess Medical Ct Inc | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| WO2016037154A1 (en) * | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant hiv-1 envelope proteins and their use |
| WO2016138525A1 (en) | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| PT3512543T (pt) * | 2016-09-15 | 2020-10-13 | Janssen Vaccines & Prevention Bv | Trímero que estabiliza mutações das proteínas do envelope do hiv |
-
2017
- 2017-05-01 IL IL299962A patent/IL299962A/en unknown
- 2017-05-01 WO PCT/US2017/030375 patent/WO2017192434A1/en not_active Ceased
- 2017-05-01 CN CN201780027483.6A patent/CN109153704A/zh active Pending
- 2017-05-01 EA EA201892233A patent/EA201892233A1/ru unknown
- 2017-05-01 SG SG11201809387QA patent/SG11201809387QA/en unknown
- 2017-05-01 CA CA3022826A patent/CA3022826A1/en active Pending
- 2017-05-01 EP EP17793064.1A patent/EP3452494A4/en active Pending
- 2017-05-01 AU AU2017259275A patent/AU2017259275C1/en active Active
- 2017-05-01 JP JP2018557105A patent/JP7046832B2/ja active Active
- 2017-05-01 MX MX2018013455A patent/MX2018013455A/es unknown
- 2017-05-01 BR BR112018072248-0A patent/BR112018072248A2/pt active IP Right Grant
-
2018
- 2018-10-24 IL IL262582A patent/IL262582B2/en unknown
- 2018-10-29 ZA ZA2018/07216A patent/ZA201807216B/en unknown
- 2018-10-31 US US16/176,200 patent/US10647748B2/en active Active
-
2020
- 2020-02-03 US US16/780,495 patent/US11236134B2/en active Active
-
2021
- 2021-08-25 AU AU2021221582A patent/AU2021221582B2/en active Active
- 2021-12-16 US US17/553,070 patent/US11767347B2/en active Active
-
2023
- 2023-08-15 US US18/449,739 patent/US20240083954A1/en not_active Abandoned
-
2024
- 2024-08-28 US US18/817,389 patent/US20250122247A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3452494A4 (en) | 2020-01-01 |
| CN109153704A (zh) | 2019-01-04 |
| IL262582B2 (en) | 2023-06-01 |
| EA201892233A1 (ru) | 2019-07-31 |
| JP7046832B2 (ja) | 2022-04-04 |
| CA3022826A1 (en) | 2017-11-09 |
| SG11201809387QA (en) | 2018-11-29 |
| US11236134B2 (en) | 2022-02-01 |
| US20250122247A1 (en) | 2025-04-17 |
| AU2017259275A1 (en) | 2018-11-15 |
| US20220098244A1 (en) | 2022-03-31 |
| ZA201807216B (en) | 2020-01-29 |
| IL299962A (en) | 2023-03-01 |
| BR112018072248A2 (pt) | 2019-02-12 |
| US10647748B2 (en) | 2020-05-12 |
| JP2019522626A (ja) | 2019-08-15 |
| AU2021221582A1 (en) | 2021-10-07 |
| WO2017192434A1 (en) | 2017-11-09 |
| US20240083954A1 (en) | 2024-03-14 |
| AU2017259275C1 (en) | 2022-01-27 |
| EP3452494A1 (en) | 2019-03-13 |
| US20190048043A1 (en) | 2019-02-14 |
| US20200165303A1 (en) | 2020-05-28 |
| IL262582A (en) | 2018-12-31 |
| AU2017259275B2 (en) | 2021-06-24 |
| AU2021221582B2 (en) | 2022-10-20 |
| US11767347B2 (en) | 2023-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013455A (es) | Composiciones y metodos relacionados con inmunogenos de vih-1. | |
| CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| EA201800108A1 (ru) | Вакцинные композиции для профилактики абровирусных инфекций | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| WO2018067582A3 (en) | Hiv-1 env fusion peptide immunogens and their use | |
| EP4549546A3 (en) | Dendritic cell generator | |
| MX374931B (es) | Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina. | |
| BR112017022430A2 (pt) | ?dispersões, processos para preparar dispersões e partículas sólidas das dispersões, uso das dispersões, preparações, e, partículas sólidas? | |
| MX2017012389A (es) | Vacuna del virus de la parotiditis recombinante jeryl lynn2. | |
| IN2014DN09445A (https=) | ||
| PH12018500645A1 (en) | Hiv antibody compositions and methods of use | |
| MX2015010763A (es) | Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento. | |
| MX2022000393A (es) | Metodo. | |
| EA202190296A1 (ru) | Клетки, дифференцированные из плюрипотентных клеток, полученных методами иммуноинженерии | |
| MX2019014651A (es) | Regimen de dosificacion de 21 dias para proteinas de fusion que comprenden el factor ix y albumina humana para el tratamiento profilactico de hemofilia y metodos del mismo. | |
| MX2017015705A (es) | Modulador de celulas t potencializado capaz de modular la respuesta inmune, especificamente diseñado para su uso terapeutico como adyuvante potencializador de vacunas virales. | |
| TH173081A (th) | วัคซีนของไทรเมอร์ของถุงหุ้ม (Env) ของไวรัสโรคภูมิคุ้มกันบกพร่องของ มนุษย์ซึ่งทำให้เกิดเสถียรภาพ (HIV) และวิธีการของการใช้ที่เหมือนกัน | |
| SG10201903292SA (en) | A drug delivery composition | |
| EP4674985A3 (en) | Compositions and methods related to characterizing proviral reservoirs | |
| EA201691202A1 (ru) | Флагеллин-содержащие белковые наночастицы в качестве платформы для вакцины |